EMA Withdrawn: Glidipion (previously Pioglitazone Actavis Group) (pioglitazone hydrochloride) — Actavis Group PTC ehf

View source ↗

Summary

The EMA has withdrawn Glidipion (pioglitazone hydrochloride) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glidipion (pioglitazone hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Actavis Group PTC ehf. Decision date: 11/06/2020